CHANGES OF ET-1, GDF-15 AND COPEPTIN BEFORE AND AFTER TREATMENT IN PATIENTS WITH PULMONARY EMBOLISM AND THEIR SIGNIFICANCE

Introduction: The objective of this study was to investigate the changes of serum endothelin-1 (ET-1), growth differentiation factor-15 (GDF-15) and Copeptin in patients with PE before and after treatment and their clinical significance. Materials and method: A total of 60 patients with PE from February 2019 to August 2021 were included. Before treatment, according to Caprini score, the high risk and extremely high risk were defined as PE positive group, and the middle risk and low risk were defined as PE negative group. A total of 60 healthy subjects matched with age and sex of patients in the PE group were selected as normal group. The serum levels of ET-1, GDF-15 and Copeptin were compared. Results: Levels of serum ET-1, GDF-15 and Copeptin in PE group were higher than those in the control group before treatment (all P<0.001). Before treatment, levels of serum ET-1, GDF-15 and Copeptin in PE positive group were higher than those in PE negative group (all P<0.001). Levels of serum ET-1, GDF-15 and Copeptin in PE group were lower after treatment than those before treatment in PE group (all P<0.001). Conclusion: Serum levels of ET-1, GDF-15 and Copeptin in patients with PE are related to the severity of PE. After treatment, the levels of serum ET-1, GDF-15 and Copeptin will reduce to a certain extent. The serum markers above may have certain clinical significance in evaluating the severity and prognosis in patients with PE.